The current pipeline of drugs in the US is unprecedented, said Steve Miller, MD, senior vice president and chief medical officer for Express Scripts. Like Rother, he expressed worries over the current 13% increase in drug prices and the fact that prices are expected to continue to go up. Read More
U.S. Senator Marco Rubio (R-Fla.) became the latest presidential candidate to speak out on prescription drug prices, saying that some pharmaceutical companies are engaging in “pure profiteering” and that high prices threaten to “bankrupt our system.” Read More
“It’s a new issue that’s emerged over the last few years but it’s a significant one, because it threatens to bankrupt our system,” Rubio said after being asked about drug prices by an audience member. “It’s a complex issue but it’s one we have to confront.” Read More
Republican presidential contender Marco Rubio blasted pharmaceutical company “profiteering” on high-cost prescription drugs during a campaign stop this week – a sign that drug prices are becoming a lightning rod for both parties in the election. Read More
POLITICO Group targeting drug costs enters early primary states By Brett… Read More
Across the country, Americans are finding the prices of the prescription drugs… Read More
Drug makers do not really want to explain how medicines are priced and, as a result, they have adopted an air of secrecy in which one cowboy can create havoc for an entire industry. Read More
Specialists in infectious disease are protesting a gigantic overnight increase in the price of a 62-year-old drug that is the standard of care for treating a life-threatening parasitic infection. Read More
The hepatitis C drugs, which cured a vast majority of patients in clinical trials, are essentially a one-time cost. The cholesterol drugs, by contrast, will be taken for a lifetime. At these rates, the lifetime costs could be staggering. Read More
Two powerful new drugs that can sharply lower cholesterol are vastly overpriced based on the value they provide, according to a new analysis by an independent organization that evaluates pharmaceutical costs. Read More
The pharmaceutical industry have, in recent years, focused on development of so-called specialty drugs and have priced them aggressively. These prices, such as the US$1,000 per pill price for the hepatitis C drug sofosbuvir, are alarming for patients, employers, insurers, and governments. Read More
“With several game-changing medications in the pipeline, we need to address the underlying issue of how these prices are set from the start before they hit the market,” John Rother, leader of the Campaign for Sustainable Rx Pricing, said in a statement. Read More